Spike Protein News and Research

RSS

T-cell responses after COVID-19 and vaccinations

A new study published in the journal Frontiers in immunology examines the cell-mediated immunity in BNT162b2 COVID-19 mRNA vaccinated health care workers and COVID-19 patients.

12 May 2022

Delta- and Omicron BA.1-variant specificity of B cell repertoires established by an initial Wuhan strain infection

Researchers performed an unbiased evaluation of the early memory B cell repertoire specific for the Omicron and Delta variants of SARS-CoV-2.

12 May 2022

Discovery of host co-factors necessary for SARS-CoV2 infection

A new study published in the journal EMBO Reports has reported on the shedding of two proteases, namely, ADAM10 and ADAM17, which aids in S protein-dependent molecular events.

11 May 2022

Study shows efficacy of COVID-19 vaccine in people receiving cancer treatment

People undergoing active cancer treatment, including stem cell transplant, should receive the COVID-19 vaccine, according to a study published in JAMA Oncology.

11 May 2022

Unique binding property may explain the ability of delta variant to spread more rapidly

Unlike other SARS-CoV-2 variants, the Delta variant can attach to copies of itself, forming larger aggregations, or clumps, of viral particles, suggests a study by scientists at the National Institutes of Health.

11 May 2022

Using virtual reality headsets to instruct UTSA students about protein structures

Francis Yoshimoto, assistant professor in the UTSA College of Sciences' Department of Chemistry, is introducing his Biochemistry II laboratory students to a new way of learning - using virtual reality headsets to observe and analyze protein structures.

10 May 2022

Research highlight reports on the observed differences in transmissibility and pathogenicity of Omicron vs. earlier variants of SARS-CoV-2

A new paper published in Signal Transduction and Targeted Therapy reports the observed differences in transmissibility and pathogenicity of Omicron vs. earlier variants of SARS-CoV-2.

10 May 2022

mRNA boosters enhance neutralization of SARS-CoV-2 BA.1, BA.2 and BA.3

A study recently published in the journal Cell Host & Microbe has described that all three sublineages of the omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibit similar host cell entry efficiency and are neutralized equally by antibodies generated in response to coronavirus disease 2019 (COVID-19) booster vaccination

10 May 2022

Third BNT162b2 dose elicits more durable immune response than second dose

Researchers evaluated the durability of immune responses post-third dose of the BNT162b2 vaccine against SARS-CoV-2.

9 May 2022

Using PCR-based genotyping to detect SARS-CoV-2 delta-omicron coinfection

In a recently published ‘Letter to the Editor’ in the journal Microbiology Spectrum, scientists have described the procedure of polymerase chain reaction (PCR)-based genotyping in identifying delta-omicron coinfection in clinical samples.

9 May 2022

ZF2001 vaccine safe and effective against symptomatic and severe-to-critical COVID

A new study published in the New England Journal of Medicine has discussed the efficacy and safety profile of the ZF2001 vaccine in adults, based on a randomized, placebo-controlled, multinational, double-blind phase 3 trial.

9 May 2022

Infection with SARS-CoV-2 results in antibodies against common colds

A study published in the journal Science Advances uses electron microscopy-based polyclonal epitope mapping (EMPEM) methodology to elucidate the spike epitopes of β-HCoV targeted by preexisting serum antibodies and compares them to the epitopes targeted by antibodies elicited by SARS-CoV-2 infection using electron microscopy-based polyclonal epitope mapping (EMPEM) methodology.

8 May 2022

A guide to help you keep up with the omicron subvariants

Two years into the coronavirus pandemic, Americans can be forgiven if they've lost track of the latest variants circulating nationally and around the world. We've heard of the alpha, beta, gamma, delta, and omicron variants, but a new Greek-letter variant hasn't come onto the scene in almost half a year.

6 May 2022

Marine bioactive compounds against SARS-CoV-2

A new review paper published in the journal Environmental Science and Pollution Research aimed to determine the possibilities of using biologically active compounds derived from various chemical classes of marine organisms against SARS-CoV-2 infection at various stages of the life cycle of the virus.

6 May 2022

Evaluating the findings of phase 3 clinical trial of plant-based COVID-19 vaccine

A new study has presented the safety and efficacy profiles of a plant-based adjuvanted coronavirus disease 2019 (COVID-19) vaccine in human participants.

5 May 2022

Study identifies two new Omicron lineages associated with a resurgence in infections in South Africa

Researchers assessed the emergence and evolution of SARS-CoV-2 Omicron variant in South Africa.

5 May 2022

Free SARS-CoV-2 spike protein fragments may trigger platelet activation and clot formation in COVID-19

In a recent study under review in the Nature Portfolio journal and currently available on the Research Square* preprint server, researchers investigated the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (SP) in the thrombi (or blood clots).

5 May 2022

Spike Protein News and Research

T-cell responses after COVID-19 and vaccinations

Delta- and Omicron BA.1-variant specificity of B cell repertoires established by an initial Wuhan strain infection

Discovery of host co-factors necessary for SARS-CoV2 infection

Study shows efficacy of COVID-19 vaccine in people receiving cancer treatment

Unique binding property may explain the ability of delta variant to spread more rapidly

Using virtual reality headsets to instruct UTSA students about protein structures

Research highlight reports on the observed differences in transmissibility and pathogenicity of Omicron vs. earlier variants of SARS-CoV-2

mRNA boosters enhance neutralization of SARS-CoV-2 BA.1, BA.2 and BA.3

Third BNT162b2 dose elicits more durable immune response than second dose

Using PCR-based genotyping to detect SARS-CoV-2 delta-omicron coinfection

ZF2001 vaccine safe and effective against symptomatic and severe-to-critical COVID

Infection with SARS-CoV-2 results in antibodies against common colds

A guide to help you keep up with the omicron subvariants

Marine bioactive compounds against SARS-CoV-2

Evaluating the findings of phase 3 clinical trial of plant-based COVID-19 vaccine

Study identifies two new Omicron lineages associated with a resurgence in infections in South Africa

Free SARS-CoV-2 spike protein fragments may trigger platelet activation and clot formation in COVID-19

How protection due to vaccination or previous SARS-CoV-2 infection varies for the population of the Czech Republic

Study explores SARS-CoV-2 RNA genome's functional interactions with host cell

Multivalent messenger ribonucleic acid-lipid nanoparticle vaccines against SARS-CoV-2

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News